Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of VRT106 in diffuse midline glioma or diffuse intrinsic pontine glioma
CTR20261602Phase 2Active
- Sponsor
- Virotech Pharmaceutical
- Start
- Apr 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of VRT-106 in diffuse midline glioma (DMG), diffuse intrinsic pontine glioma (DIPG), sponsored by Virotech Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
VRT-106
03
Conditions
diffuse midline glioma (DMG)diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on CTR20261602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261602.